Clinical trials: SARS-CoV 2
SARS CoV 2 Infection
A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 in Immunocompromised Individuals
This is an open-label study examining the safety and tolerability of sotrovimab, administered in two sequential doses as prophylaxis in immunocompromised patients with impaired humoral immunity against SARS-CoV-2.
- Trial name
- NCT05210101
- Testing
- Sotrovimab
- Where
- 3 sites in United States
- Volunteers
- 93 people
- Sponsor
- Sophia Koo, M.D.
Long COVID-19 Syndrome, COVID 19
Evaluating the Impact of a Functional and Cognitive Strategy in Patients With Long Covid-19
This study aims to evaluate the impact of a functional and cognitive rehabilitation strategy compared to evidence-based informational messages, on functional capacity, cognitive abilities, quality of life, and disease progression…
- Conditions
- Long COVID-19 Syndrome, COVID 19, Noncommunicable Disease, Hypertension
- Trial name
- NCT06871293
- Testing
- Functional and cognitive rehabilitation strategy, Evidence-Based Informational Support
- Where
- Colombia
- Volunteers
- 374 people
- Sponsor
- Fundación Cardioinfantil Instituto de Cardiología
SARS-CoV 2, Infection
GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19)
This clinical trial will evaluate the safety, tolerability and effectiveness of topical GLS-1200 nasal spray to reduce the incidence of confirmed, symptomatic SARS-CoV-2 infection.
- Trial name
- NCT04408183
- Testing
- GLS-1200
- Where
- 3 sites in United States
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- GeneOne Life Science, Inc.
SARS-CoV Infection, Covid19
Use of Hypochlorous Acid as Prophylaxis in Health Personnel at High Risk of Infection by SARS-CoV 2 (COVID19)
The pandemic caused by SARS-CoV-2 is a global emergency present in 6 continents including 66 countries, incurring a shortage of effective and safe therapeutic alternatives that can contribute to reducing the risk of…
- Conditions
- SARS-CoV Infection, Covid19, Infection Viral
- Trial name
- NCT04684550
- Testing
- Stabilized hypochlorous acid
- Volunteers
- healthy volunteers welcome
- Sponsor
- Hospital Universitario San Ignacio
SARS-CoV 2
Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years.
The study will be a randomized, partially-blinded, prime-boost, staggered dose-escalation Phase 1 study intended to assess the safety, tolerability, and immunogenicity of the Coronavirus-Like Particle COVID-19 Vaccine at three…
- Trial name
- NCT04450004
- Testing
- Intramuscular Vaccine
- Where
- 2 sites in Canada
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Medicago
COVID, COVID19
International SARS-CoV-2 (COVID-19) Infection Observational Study
The general aim of this study is to estimate the rate of disease progression for adults testing positive for SARS-CoV-2. The primary endpoint for this study and the basis for sample size is hospitalization or death during the 28…
- Conditions
- COVID, COVID19, SARS-CoV 2, Dyspnea
- Trial name
- ICOS (NCT04385251)
- Testing
- Data Collection
- Where
- 4 sites in United States, Argentina and 2 more
- Volunteers
- 11,973 people
- Sponsor
- University of Minnesota
COVID-19, SARS-CoV 2
Network-Targeted Strategies for Efficient Community SARS-CoV-2 (COVID-19) Sampling
The primary objective is to use "network targeted sampling design" to detect active and/or undiagnosed cases of COVID-19 in the community and determine the spread or distribution of 1) active infection, and 2) past exposure.
- Trial name
- Snowball (NCT04437706)
- Where
- United States
- Volunteers
- 602 people, healthy volunteers welcome
- Sponsor
- Duke University
COVID-19, Vaccine Reaction
Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 Vaccine
Phase II, non-randomized, open-label, comparative, national, multicenter trial in Mali, aimed to assess the humoral vaccine immune response induced by Ad26.COV2.S vaccine in 200 adults one month after receiving the complete…
- Conditions
- COVID-19, Vaccine Reaction, SARS CoV 2 Infection, Vaccine Adverse Reaction
- Trial name
- CoviComMali (NCT05409261)
- Testing
- Ad26.COV2.S
- Where
- Mali
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
Coronavirus Infection, COVID
Cytokine Adsorption in Patients With Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation
In December 2019 in the city of Wuhan in China, a series of patients with unclear pneumonia was noticed, some of whom have died of it.
- Conditions
- Coronavirus Infection, COVID, SARS-CoV 2, Respiratory Failure
- Trial name
- CYCOV-II (NCT04385771)
- Testing
- vv-ECMO + cytokine adsorption (Cytosorb adsorber), vv-ECMO only (no cytokine adsorption)
- Where
- 3 sites in Germany
- Volunteers
- 80 people
- Sponsor
- Dr. Alexander Supady
Covid-19, SARS-CoV 2
Baricitinib Compared to Standard Therapy in Patients With COVID-19
There is urgent need of an effective therapy for Covid-19. To date, the best treatment of SARS-CoV-2 infection is unknown. Baricitinib has been identified as potential treatment for 2019-nCoV acute respiratory disease, because of…
- Conditions
- Covid-19, SARS-CoV 2, SARS Pneumonia
- Trial name
- BARICIVID-19 (NCT04393051)
- Testing
- Baricitinib Oral Tablet
- Where
- Italy
- Volunteers
- 126 people
- Sponsor
- Azienda Ospedaliero, Universitaria Pisana
COVID-19 Pneumonia, Sequelae of; Infection
Assessment of Long-term Sequelae of Coronavirus Disease 2019 (COVID-19) Pneumonia With Chest CT and Pulmonary Function Tests
The goal of this prospective multicentric study is to evaluate the presence of long-term pulmonary sequelae in patients who had required hospitalization for treating COVID-19 pneumonia, trough chest CT and pulmonary function…
- Conditions
- COVID-19 Pneumonia, Sequelae of; Infection, Respiratory Function Impaired, SARS CoV 2 Infection
- Trial name
- NCT05835128
- Where
- 2 sites in Portugal
- Volunteers
- 250 people
- Sponsor
- Centro Hospitalar Universitario do Algarve
SARS CoV 2 Infection
Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients.
The objective of the study is to evaluate the efficacy and safety of two different doses of raloxifene orally administered compared to placebo in patients with early diagnosis of paucisymptomatic COVID-19.
- Trial name
- NCT05172050
- Testing
- Raloxifene
- Where
- 11 sites in France, Italy and 1 more
- Volunteers
- 61 people
- Sponsor
- Dompé Farmaceutici S.p.A
COVID-19 Pandemic, Immunogenicity
Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults
Under protocol versions 1.01-1.06: The five recently emerged SARS-CoV2 variants that were designated as VOCs are the Alpha variant, Beta variant, Gamma variant, Delta variant and the Omicron variant.
- Conditions
- COVID-19 Pandemic, Immunogenicity, SARS CoV 2 Infection, COVID-19
- Trial name
- SH-MO-214 (NCT05383560)
- Testing
- mRNA-1273.214 Vaccine, MRNA-1273 Vaccine, MRNA-1273.222 Vaccine
- Where
- Israel
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Sheba Medical Center
Covid-19, SARS-CoV 2
COVID-19 Biorepository
Establish a COVID-19 biorepository to aid in developing our knowledge of the disease.
- Conditions
- Covid-19, SARS-CoV 2, Coronavirus, COVID
- Trial name
- NCT04568148
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- University of Kansas Medical Center
SARS (Severe Acute Respiratory Syndrome)
Quercetin In The Treatment Of SARS-COV 2
In 1937, Albert Szent-Gyorgyi received a Nobel Prize for discovering vitamin C and flavonoids, as well as for exploring their biochemical properties.
- Trial name
- QUERCOV (NCT04853199)
- Testing
- Quercetin
- Where
- 2 sites in Tunisia
- Volunteers
- 200 people
- Sponsor
- Hôpital Universitaire Sahloul
Covid19
SERUR: COVID-19 Serological Survey of Staff From the University Reims-Champagne Ardennes
This study was designed to determine, in a screening situation within the framework of university preventive medicine, the prevalence of positive anti-SARS-Cov 2 serology among the staff of the University of Reims…
- Trial name
- SERUR (NCT04816084)
- Testing
- Anti-SARS-CoV2 Serology
- Where
- France
- Volunteers
- 389 people, healthy volunteers welcome
- Sponsor
- Université de Reims Champagne-Ardenne
Respiratory Viral Infections, Influenza
Effect of MxA Guidance on Antiviral Treatment in Respiratory Viral Infections
The goal of this clinical trial is to evaluate the effects of myxovirus resistance protein A (MxA)-guided antiviral treatment on treatment duration and adverse outcomes in adults hospitalized with influenza or COVID-19, compared…
- Conditions
- Respiratory Viral Infections, Influenza, SARS CoV 2 Infection
- Trial name
- NCT07892872
- Testing
- Baseline MxA testing, Serial MxA testing, MxA result feedback and antiviral treatment recommendations
- Where
- China
- Volunteers
- 618 people
- Sponsor
- Capital Medical University
SARS CoV 2 Infection
Sisonke 2 - A COVID-19 Vaccine Boost Open Label Study.
To evaluate the effectiveness of the single dose Ad26.COV2.S COVID-19 vaccine plus a homologous boostwith Ad26.COV2.S COVID-19 vaccine among Sisonke participants as compared to unboosted Sisonkeparticipants; vaccinated; and…
- Trial name
- Sisonke Boost (NCT05148845)
- Testing
- Sisonke Heterologous mRNA-1273 boost after prime with Ad26.COV2.S
- Where
- 31 sites in South Africa
- Volunteers
- 500,000 people, healthy volunteers welcome
- Sponsor
- Wits Health Consortium (Pty) Ltd
Healthy Participants
Food Effect Study to Evaluate the Effect of High-Fat Meal on the Relative Bioavailability of PF-07321332 Boosted With Ritonavir in Healthy Adult Participants
This is a Phase 1, open label, single dose, randomized, 2-treatment, 2-sequence, 2-period crossover study to evaluate the effect of high-fat meal on the relative bioavailability of PF-07321332 boosted with ritonavir following…
- Trial name
- NCT05129475
- Testing
- PF-07321332/ritonavir, Ritonavir
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Covid19, Sars-cov 2
Fase I Clinical Trial on NK Cells for COVID-19
Coronavirus Disease 2019 (COVID-19) is spreading worldwide and has become a public health emergency of major international concern. Currently, no specific drugs or vaccines are available.
- Trial name
- NCT04634370
- Testing
- Natural Killer Cells infusion
- Where
- Brazil
- Volunteers
- 24 people
- Sponsor
- Hospital de Clinicas de Porto Alegre